SML2357
Isavuconazole
≥98% (HPLC), powder, fungal sterol biosynthesis inhibitor
别名:
(2R,3R)-3-[4-(4-Cyanophenyl)thiazol-2-yl]-2-(2,5-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, 1-[(2R,3R)-3-[4-(4-Cyanophenyl)thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazole, 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile, BAL 4815, RO 0094815
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
product name
Isavuconazole, ≥98% (HPLC)
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
2-8°C
InChI
1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1
InChI 密鑰
DDFOUSQFMYRUQK-RCDICMHDSA-N
應用
Isavuconazole has been used as an antifungal agent to test its effect on Mucor circinelloides gene transcription. It has also been used
to analyze its in vitro activity against isolates from the R. argillacea species complex A. fumigatus, N. hiratsukae and C. parapsilosis.
to analyze its in vitro activity against isolates from the R. argillacea species complex A. fumigatus, N. hiratsukae and C. parapsilosis.
生化／生理作用
Isavuconazole is a triazole antifungal drug. It inhibits fungal sterol biosynthesis by inhibition of cytochrome P450 sterol 14-α-demethylase (CYP51), an enzyme in the sterol biosynthesis pathway that leads from lanosterol to ergosterol. It has been approved for the treatment of both invasive aspergillosis and invasive mucormycosis.
訊號詞
Warning
危險聲明
危險分類
Repr. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
M-P Ledoux et al.
Journal de mycologie medicale, 28(1), 15-22 (2018-03-20)
Isavuconazole, the active moiety of its prodrug isavuconazonium, is a new extended-spectrum triazole whose activity against yeasts, molds, including Aspergillus and mucorales, and dimorphic fungi has been shown in vitro and in preclinical models. The most relevant pharmacokinetics features are
Jeffrey M Rybak et al.
Pharmacotherapy, 35(11), 1037-1051 (2015-11-26)
Coinciding with the continually increasing population of immunocompromised patients worldwide, the incidence of invasive fungal infections has grown over the past 4 decades. Unfortunately, infections caused by both yeasts such as Candida and molds such as Aspergillus or Mucorales remain
Seyedmojtaba Seyedmousavi et al.
Antimicrobial agents and chemotherapy, 59(5), 2855-2866 (2015-03-11)
Azole resistance is an emerging problem in Aspergillus fumigatus which translates into treatment failure. Alternative treatments with new azoles may improve therapeutic outcome in invasive aspergillosis (IA) even for strains with decreased susceptibility to current azoles. The in vivo efficacy
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门